We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Real-Time Assay Evaluated for Two Sexually Transmitted Diseases

By LabMedica International staff writers
Posted on 21 Apr 2020
Print article
Image: The Abbott RealTime CT/NG assay provides detection of Chlamydia trachomatis and Neisseria gonorrhoeae with proven clinical performance in sexually transmitted disease testing (Photo courtesy of Abbott Laboratories).
Image: The Abbott RealTime CT/NG assay provides detection of Chlamydia trachomatis and Neisseria gonorrhoeae with proven clinical performance in sexually transmitted disease testing (Photo courtesy of Abbott Laboratories).
Chlamydia trachomatis and Neisseria gonorrhoeae are the two most commonly reported sexually transmitted infections (STIs) in the USA and the numbers of cases are increasing. C. trachomatis and N. gonorrhoeae infections in the rectum and pharynx are important extragenital reservoirs of infection.

Due to their high sensitivity and specificity, nucleic acid amplification tests (NAATs) have become the recommended method for detecting N. gonorrhoeae and C. trachomatis infections of the urogenital tract. The Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) recommends screening of all sexually-active men who have sex with men (MSM) for rectal C. trachomatis and N. gonorrhoeae infections and pharyngeal N. gonorrhoeae, at least annually.

Scientists from the David Geffen School of Medicine (Los Angeles, CA, USA) examined the analytical performance of the Abbott RealTime CT/NG assay (Abbott Laboratories, Abbott Park, IL, USA), including the limit of detection, inclusivity, and analytical specificity for C. trachomatis and N. gonorrhoeae in rectal and pharyngeal specimens. All tests were performed on the Abbott m2000 RealTime system. Elementary Bodies (EB)/mL for C. trachomatis and colony-forming units (CFU)/mL for N. gonorrhoeae, in clinical rectal and pharyngeal swab matrices were measured. Inclusivity was performed against 12 serovars of C. trachomatis and seven strains of N. gonorrhoeae. The analytical specificity was performed using 28 different bacteria and viruses.

The limit of detection for C. trachomatis was 2.56 EB/mL in pharyngeal specimens and 12.8 EB/mL in rectal specimens. The limit of detection for N. gonorrhoeae was 0.0256 CFU/mL for both pharyngeal and rectal specimens. The inclusivity and analytical specificity were 100% for both rectal and pharyngeal specimens. In total, there were 80 specimens tested by the second laboratory. All 40 rectal and pharyngeal specimens spiked with C. trachomatis and all 40 rectal and pharyngeal specimens spiked with N. gonorrhoeae tested positive. C. trachomatis was detected in 0/20 of the N. gonorrhoeae-spiked samples from each anatomic site and N. gonorrhoeae was detected in 0/20 C. trachomatis-spiked samples from each anatomic site.

The authors concluded that their analytical performance data demonstrate that the Abbott CT/NG RealTime assay is an accurate, sensitive, and specific assay in rectal and pharyngeal specimens, supporting the potential of the assay for detection of rectal and pharyngeal C. trachomatis and N. gonorrhoeae infections. The study was published on April 2, 2020 in The Journal of Molecular Diagnostics.




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more